Mechanistic Understanding of Curcumin’s Therapeutic Effects in Lung Cancer
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Lung cancer is among the most common cancers with a high mortality rate worldwide. Despite the significant advances in diagnostic and therapeutic approaches, lung cancer prognoses and survival rates remain poor due to late diagnosis, drug resistance, and adverse effects. Therefore, new intervention therapies, such as the use of natural compounds with decreased toxicities, have been considered in lung cancer therapy. Curcumin, a natural occurring polyphenol derived from turmeric (Curcuma longa) has been studied extensively in recent years for its therapeutic effects. It has been shown that curcumin demonstrates anti-cancer effects in lung cancer through various mechanisms, including inhibition of cell proliferation, invasion, and metastasis, induction of apoptosis, epigenetic alterations, and regulation of microRNA expression. Several in vitro and in vivo studies have shown that these mechanisms are modulated by multiple molecular targets such as STAT3, EGFR, FOXO3a, TGF-β, eIF2α, COX-2, Bcl-2, PI3KAkt/mTOR, ROS, Fas/FasL, Cdc42, E-cadherin, MMPs, and adiponectin. In addition, limitations, strategies to overcome curcumin bioavailability, and potential side effects as well as clinical trials were also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066 · cited 2×
“To date, the standard treatments for the majority of lung cancer patients including SCLC and NSCLC are surgery, chemotherapy, radiation therapy, or a combination of these treatments [5].”
BackgroundRegulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012 · cited 1×
“Histones (H3, H4, H2A, H2B and H1) are highly conserved core proteins of chromatin structure that subject to posttranslational modifications including lysine acetylation, ADP-ribosylation, ubiquitination, and sumoylation that occur on N- or C-terminal tail domains [220,221].”
BackgroundBioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 1×
“Pharmacokinetic profile studies of curcumin have revealed that curcumin has poor absorption as well as rapid metabolism that severely renders its bioavailability [250,251].”
BackgroundRegulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · cited 1×
“Therefore, dysregulation of the cell cycle can cause excessive or uncontrolled proliferation, contributing to the development of malignant tumor cells [22,23].”
BackgroundMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“MMP-9 may act as an angiogenic switch due to its ability to increase the bioavailability of angiogenic factors including VEGF, which is the most potent mediator of tumor vasculature [188,189].”
BackgroundBushati, N., & Cohen, S. M. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123406 · Cited by 2,750
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · cited 1×
“STAT3 is activated through STAT3 tyrosine phosphorylation by Janus Kinase (JAK) and growth factor receptor tyrosine kinase in response to the bonds of cell surface receptors to ligands such as epidermal growth factor (EGF), interferons and interleukin-6 (IL-6) [25,26].”
BackgroundThe let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells
Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., Shingara, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1083 · Cited by 1,224
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765 · cited 1×
“Phosphatidylinositol-3-kinase (PI3K), a lipid kinase family, is activated by the binding of extracellular growth factors to transmembrane receptor tyrosine kinases (RTKs) such as the vascular endothelial growth factor receptor (VEGFR), EGFR, insulin-like growth factor 1 receptor (IGF-1R), fibroblast growth factor rece…”
BackgroundLevy, D. E., & Lee, C.-K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215650 · Cited by 734
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Thioredoxin Reductase Is Irreversibly Modified by Curcumin
Fang, J., Lu, J., & Holmgren, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414645200 · Cited by 521
Koerner, A., Kratzsch, J., & Kiess, W. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.008 · Cited by 471 · cited 1×
“Adiponectin is a peptide hormone produced solely by adipose tissue, which has the function to serve as an anti-atherogenic hormone by inhibiting proliferation of vascular smooth muscle cells and endothelia cells [193].”
BackgroundMicroRNA: A novel target of curcumin in cancer therapy
Mirzaei, H., Masoudifar, A., Sahebkar, A., Zare, N., Sadri Nahand, J., Rashidi, B., Mehrabian, E., Mohammadi, M., Mirzaei, H. R., & Jaafari, M. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26055 · Cited by 236
Zhao, M., Gao, F.-H., Wang, J.-Y., Liu, F., Yuan, H.-H., Zhang, W.-Y., & Jiang, B. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.002 · Cited by 161
Proteomics analysis of E-cadherin knockdown in epithelial breast cancer cells
Vergara, D., Simeone, P., Latorre, D., Cascione, F., Leporatti, S., Trerotola, M., Giudetti, A. M., Capobianco, L., Lunetti, P., Rizzello, A., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.10.034 · Cited by 41
Cited by
Fu, Y.-S., Chen, T.-H., Weng, L., Huang, L., Lai, D., & Weng, C.-F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111888 · Cited by 271
Current Status of Research on Losartan in Tumour Therapy
Wang, H., Yuan, S., & Wang, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70985 · Cited by 11
“Similar microenvironment-targeting strategies, such as the use of curcumin to overcome multidrug resistance in lung adenocarcinoma, remain limited by poor bioavailability [145, 146].”
Metadata
- Authors
- Wan Mohd Tajuddin, W. N. B., Lajis, N. H., Abas, F., Othman, I., & Naidu, R.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2019-12-06
- Volume
- 11
- Issue
- 12
- Pages
- 2989
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2991728669
- Cited by
- 162
- References
- 25
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.